Push for Alternative Therapies Prods Researchers Towards Psilocybin FinancialBuzz.com News Commentary NEW YORK, Dec. 15, 2020 /PRNewswire/ -- The psychedelics market is currently navigating a similar legal situation to the one the cannabis market found itself in for many years. Psychedelics are not legal for recreational use in Canada or the United States, yet medical research on the efficiency of such products may help reduce some of the stigma around them. In fact, some major developments have already begun to change the landscape for the better in this market. For example, earlier in 2019, the state of Colorado became the first state to decriminalize Magic Mushrooms (mushrooms containing psilocybin), taking the substance on a similar path to legalization as that of cannabis. Then, in November 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant. Currently, despite the obstacles imposed by the legal status for such products, the psychedelic drugs market is expected to expand with a CAGR of 16.3%, reaching USD 6,859.95 Million by 2027, according to